Search

Your search keyword '"Projectafdeling ALS"' showing total 357 results

Search Constraints

Start Over You searched for: Author "Projectafdeling ALS" Remove constraint Author: "Projectafdeling ALS"
Sorry, I don't understand your search. ×
357 results on '"Projectafdeling ALS"'

Search Results

1. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

2. Assessment of risk of ALS conferred by the GGGGCC hexanucleotide repeat expansion in C9orf72 among first-degree relatives of patients with ALS carrying the repeat expansion

3. Mutations in the tail and rod domains of the neurofilament heavy-chain gene increase the risk of ALS

4. A comparison between bioelectrical impedance analysis and air-displacement plethysmography in assessing fat-free mass in patients with motor neurone diseases: a cross-sectional study

5. Correction to: The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration (Nature Communications, (2022), 13, 1, (6901), 10.1038/s41467-022-34620-y)

6. Functional network dynamics revealed by EEG microstates reflect cognitive decline in amyotrophic lateral sclerosis

7. Natural History of Mandibular Function in Spinal Muscular Atrophy Types 2 and 3

8. Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators: A Systematic Review and Meta-Analysis

11. Association Between Hypothalamic Volume and Metabolism, Cognition, and Behavior in Patients With Amyotrophic Lateral Sclerosis

12. A 21-bp deletion in the complement regulator CD55 promotor region is associated with multifocal motor neuropathy and its disease course

13. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD)

14. Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study

15. Remote monitoring of amyotrophic lateral sclerosis using wearable sensors detects differences in disease progression and survival: a prospective cohort study

16. Revisiting distinct nerve excitability patterns in patients with amyotrophic lateral sclerosis

17. The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials

19. (Dis)entangling ALS

20. Feasibility and Reproducibility of Isokinetic Dynamometry in Children with Neuromuscular Diseases

21. ALS-associated C21ORF2 variant disrupts DNA damage repair, mitochondrial metabolism, neuronal excitability and NEK1 levels in human motor neurons

22. Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study

23. ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes

24. Molecular pathology, developmental changes and synaptic dysfunction in (pre-) symptomatic human C9ORF72-ALS/FTD cerebral organoids

25. Monitoring Nusinersen Treatment Effects in Children with Spinal Muscular Atrophy with Quantitative Muscle MRI

26. The Effects of a Blended Care Intervention in Partners of Patients With Acquired Brain Injury - Results of the CARE4Carer Randomized Controlled Trial

28. Familial motor neuron disease: co-occurrence of PLS and ALS (-FTD)

30. Early amyloid-induced changes in microglia gene expression in male APP/PS1 mice

31. Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS

32. A Health App Platform Providing a Budget to Purchase Preselected Apps as an Innovative Way to Support Public Health: Qualitative Study With End Users and Other Stakeholders

34. Simulating progressive motor neuron degeneration and collateral reinnervation in motor neuron diseases using a dynamic muscle model based on human single motor unit recordings

35. Treatment of multiple traumatized adolescents by enhancing regulation skills and reducing trauma related symptoms: rationale, study design, and methods of randomized controlled trial (the Mars-study)

36. Portable fixed dynamometry enables home-based, reliable assessment of muscle strength in patients with amyotrophic lateral sclerosis: a pilot study

37. Feasibility and tolerability of multimodal peripheral electrophysiological techniques in a cohort of patients with spinal muscular atrophy

38. Enhanced low-threshold motor unit capacity during endurance tasks in patients with spinal muscular atrophy using pyridostigmine

39. Multidisciplinary end-of-life care for a patient with amyotrophic lateral sclerosis requesting euthanasia

40. Control in the absence of choice: A qualitative study on decision-making about gastrostomy in people with amyotrophic lateral sclerosis, caregivers, and healthcare professionals

41. Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial

42. A randomized, double-blind, placebo-controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis

43. Hybrid Controlled Clinical Trials Using Concurrent Registries in Amyotrophic Lateral Sclerosis: A Feasibility Study

44. Stress imaging in patients with a Fontan circulation: A systematic review

45. Diagnostic accuracy of nerve excitability and compound muscle action potential scan-derived biomarkers in amyotrophic lateral sclerosis

46. Multifocal motor neuropathy is not associated with altered innate immune responses to endotoxin

47. Frequency of euthanasia, factors associated with end-of-life practices, and quality of end-of-life care in patients with amyotrophic lateral sclerosis in the Netherlands: a population-based cohort study

48. Genetic variability in sporadic amyotrophic lateral sclerosis

49. Continuous Theta-Burst Stimulation of the Contralesional Primary Motor Cortex for Promotion of Upper Limb Recovery After Stroke: A Randomized Controlled Trial

50. Courage-als: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

Catalog

Books, media, physical & digital resources